Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial

医学 2019年冠状病毒病(COVID-19) 肝素 2019-20冠状病毒爆发 重症监护医学 内科学 病毒学 传染病(医学专业) 爆发 疾病
作者
Alex C. Spyropoulos,Mark Goldin,Dimitrios Giannis,Wassim Diab,Janice Wang,Sameer Khanijo,Andrea Mignatti,Eugenia Gianos,Marc C. Cohen,Gulru Sharifova,Jeet M. Lund,Alfonso Javier Tafur,Paul A. Lewis,Kevin P. Cohoon,Husneara Rahman,Cristina P. Sison,MARTIN L. LESSER,Kanta Ochani,Nirav Agrawal,Judith A. Hsia
出处
期刊:JAMA Internal Medicine [American Medical Association]
卷期号:181 (12): 1612-1612 被引量:503
标识
DOI:10.1001/jamainternmed.2021.6203
摘要

Importance: Hospitalized patients with COVID-19 are at risk for venous and arterial thromboembolism and death. Optimal thromboprophylaxis dosing in high-risk patients is unknown. Objective: To evaluate the effects of therapeutic-dose low-molecular-weight heparin (LMWH) vs institutional standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19. Design, Setting, and Participants: The HEP-COVID multicenter randomized clinical trial recruited hospitalized adult patients with COVID-19 with D-dimer levels more than 4 times the upper limit of normal or sepsis-induced coagulopathy score of 4 or greater from May 8, 2020, through May 14, 2021, at 12 academic centers in the US. Interventions: Patients were randomized to institutional standard prophylactic or intermediate-dose LMWH or unfractionated heparin vs therapeutic-dose enoxaparin, 1 mg/kg subcutaneous, twice daily if creatinine clearance was 30 mL/min/1.73 m2 or greater (0.5 mg/kg twice daily if creatinine clearance was 15-29 mL/min/1.73 m2) throughout hospitalization. Patients were stratified at the time of randomization based on intensive care unit (ICU) or non-ICU status. Main Outcomes and Measures: The primary efficacy outcome was venous thromboembolism (VTE), arterial thromboembolism (ATE), or death from any cause, and the principal safety outcome was major bleeding at 30 ± 2 days. Data were collected and adjudicated locally by blinded investigators via imaging, laboratory, and health record data. Results: Of 257 patients randomized, 253 were included in the analysis (mean [SD] age, 66.7 [14.0] years; men, 136 [53.8%]; women, 117 [46.2%]); 249 patients (98.4%) met inclusion criteria based on D-dimer elevation and 83 patients (32.8%) were stratified as ICU-level care. There were 124 patients (49%) in the standard-dose vs 129 patients (51%) in the therapeutic-dose group. The primary efficacy outcome was met in 52 of 124 patients (41.9%) (28.2% VTE, 3.2% ATE, 25.0% death) with standard-dose heparins vs 37 of 129 patients (28.7%) (11.7% VTE, 3.2% ATE, 19.4% death) with therapeutic-dose LMWH (relative risk [RR], 0.68; 95% CI, 0.49-0.96; P = .03), including a reduction in thromboembolism (29.0% vs 10.9%; RR, 0.37; 95% CI, 0.21-0.66; P < .001). The incidence of major bleeding was 1.6% with standard-dose vs 4.7% with therapeutic-dose heparins (RR, 2.88; 95% CI, 0.59-14.02; P = .17). The primary efficacy outcome was reduced in non-ICU patients (36.1% vs 16.7%; RR, 0.46; 95% CI, 0.27-0.81; P = .004) but not ICU patients (55.3% vs 51.1%; RR, 0.92; 95% CI, 0.62-1.39; P = .71). Conclusions and Relevance: In this randomized clinical trial, therapeutic-dose LMWH reduced major thromboembolism and death compared with institutional standard heparin thromboprophylaxis among inpatients with COVID-19 with very elevated D-dimer levels. The treatment effect was not seen in ICU patients. Trial Registration: ClinicalTrials.gov Identifier: NCT04401293.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
充电宝的应助被科研通管家采纳,获得10
刚刚
1097发布了新的文献求助10
刚刚
aajhajkahna的应助被科研通管家采纳,获得10
刚刚
汉堡包的应助被科研通管家采纳,获得10
1秒前
深情安青的应助被科研通管家采纳,获得10
1秒前
1秒前
Owen的应助被科研通管家采纳,获得10
1秒前
心香驳回了MM的应助
1秒前
小马甲的应助被科研通管家采纳,获得10
1秒前
急急急发布了新的文献求助10
1秒前
molihuakai的应助被科研通管家采纳,获得10
1秒前
英俊的铭的应助被科研通管家采纳,获得10
1秒前
1秒前
n11发布了新的文献求助10
1秒前
Owen的应助被科研通管家采纳,获得10
1秒前
vnewgnl的应助被科研通管家采纳,获得20
2秒前
2秒前
星1993发布了新的文献求助10
2秒前
2秒前
春申君发布了新的文献求助10
2秒前
紧张的谷槐完成签到,获得积分10
2秒前
上官若男的应助被科研通管家采纳,获得10
2秒前
Hello的应助被科研通管家采纳,获得10
2秒前
小蘑菇的应助被科研通管家采纳,获得10
2秒前
orixero的应助被科研通管家采纳,获得10
2秒前
CipherSage的应助被鱿鱼的云朵采纳,获得10
2秒前
天天快乐的应助被科研通管家采纳,获得10
3秒前
鲁万仇发布了新的文献求助10
3秒前
syvshc的应助被科研通管家采纳,获得10
3秒前
田様的应助被科研通管家采纳,获得10
3秒前
852的应助被科研通管家采纳,获得10
3秒前
思源的应助被科研通管家采纳,获得10
3秒前
星辰大海的应助被科研通管家采纳,获得10
3秒前
爆米花的应助被科研通管家采纳,获得10
3秒前
小蘑菇的应助被科研通管家采纳,获得10
3秒前
共享精神的应助被科研通管家采纳,获得10
4秒前
威fly完成签到,获得积分10
4秒前
dxxxxx完成签到,获得积分10
4秒前
Hello的应助被科研通管家采纳,获得10
4秒前
CodeCraft的应助被科研通管家采纳,获得10
4秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183142
求助须知:如何正确求助?哪些是违规求助? 9572420
关于积分的说明 21825253
捐赠科研通 7779922
什么是DOI,文献DOI怎么找? 3433850
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480124